Alembic Pharmaceuticals (BOM:533573) ROCE % : 15.75% (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Alembic Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alembic Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 15.75%.

Alembic Pharmaceuticals ROCE % Historical Data

The historical data trend for Alembic Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alembic Pharmaceuticals ROCE % Chart

Alembic Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

27.29

28.64

11.87

8.13

14.43

Alembic Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															12.94	17.20	15.53	13.64	15.75

Alembic Pharmaceuticals ROCE % Calculation

Alembic Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	6880.2	/	( ( (61828.3 - 16369.2)	+	(64455.8 - 14550) )	/ 2 )
	=	6880.2	/	( (45459.1	+	49905.8)	/ 2 )
	=	6880.2	/	47682.45
	=	14.43 %

Alembic Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	7969.2	/	( ( (0 - 0)	+	(72302.5 - 21718.2) )	/ 1 )
	=	7969.2	/	( ( 0	+	50584.3 )	/ 1 )
	=	7969.2	/	50584.3
	=	15.75 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Alembic Pharmaceuticals (BOM:533573) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alembic Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Alembic Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alembic Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » ROCE %

Traded in Other Exchanges

APLLTD:India

Address

Alembic Road, Vadodara, GJ, IND, 390 003

Website

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Alembic Pharmaceuticals Headlines

No Headlines